PFE Pfizer Inc

Pfizer Inc. (PFE) filed a Form 8K - Changes in Company Executive Management - with the U.S Securities and Exchange Commission on February 08, 2016.

On February 8, 2016, Pfizer Inc. (the "Company") announced that Geno Germano, Group President, Global Innovative Pharma Business, will be leaving the Company. The Company also announced that, effective immediately and through the closing of the pending transaction between Pfizer and Allergan plc ("Allergan"), Pfizer's Global Innovative Pharma business and its Vaccines, Oncology and Consumer Healthcare business will operate separately under the leadership of Albert Bourla, currently Group President, Vaccines, Oncology and Consumer Healthcare. The Company also announced the expected executive leadership team for the combined Pfizer-Allergan organization upon closing of the pending transaction with Allergan.

The related press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

The full text of this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/78003/000007800316000058/n8k2516.htm

Any exhibits and associated documents for this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/78003/000007800316000058/0000078003-16-000058-index.htm

Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.

(END) Dow Jones Newswires

February 08, 2016 17:36 ET (22:36 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.